NCT03886701 - Doravirine, Rifapentine and Isoniazid Interaction | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 22, 2019

Primary Completion Date

May 20, 2019

Study Completion Date

May 20, 2019

Conditions

Latent TuberculosisHuman Immunodeficiency VirusRifamycins Causing Adverse Effects in Therapeutic UseDrug Interaction Potentiation

Interventions

DRUG

Doravirine (DOR)

Non-nucleoside reverse transcriptase inhibitor indicated for the treatment of HIV-1 infection in adults in combination with other antiretroviral agents.

DRUG

Rifapentine (RPT)

Rifamycin anti-tuberculosis agent indicated for the treatment of latent and active tuberculosis infection.

DRUG

Isoniazid (INH)

Anti-tuberculosis agent indicated for the treatment of latent and active tuberculosis infection.

Trial Locations (1)

19107

Thomas Jefferson University Clinical Research Unit, Philadelphia

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Walter K. Kraft

OTHER